Literature DB >> 33327641

Persistence of COVID-19 Symptoms after Recovery in Mexican Population.

Carlos E Galván-Tejada1, Cintya Fabiola Herrera-García2, Susana Godina-González2, Karen E Villagrana-Bañuelos1, Juan Daniel De Luna Amaro3, Karla Herrera-García2, Carolina Rodríguez-Quiñones2, Laura A Zanella-Calzada4, Julio Ramírez-Barranco5, Jocelyn L Ruiz de Avila6, Fuensanta Reyes-Escobedo2, José M Celaya-Padilla1, Jorge I Galván-Tejada1, Hamurabi Gamboa-Rosales1, Mónica Martínez-Acuña2, Alberto Cervantes-Villagrana2, Bruno Rivas-Santiago7, Irma E Gonzalez-Curiel2.   

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease (COVID-19), a highly contagious infectious disease that has caused many deaths worldwide. Despite global efforts, it continues to cause great losses, and leaving multiple unknowns that we must resolve in order to face the pandemic more effectively. One of the questions that has arisen recently is what happens, after recovering from COVID-19. For this reason, the objective of this study is to identify the risk of presenting persistent symptoms in recovered from COVID-19. This case-control study was conducted in one state of Mexico. Initially the data were obtained from the participants, through a questionnaire about symptoms that they had at the moment of the interview. Initially were captured the collected data, to make a dataset. After the pre-processed using the R project tool to eliminate outliers or missing data. Obtained finally a total of 219 participants, 141 recovered and 78 controls. It was used confidence level of 90% and a margin of error of 7%. From results it was obtained that all symptoms have an associated risk in those recovered. The relative risk of the selected symptoms in the recovered patients goes from 3 to 22 times, being infinite for the case of dyspnea, due to the fact that there is no control that presents this symptom at the moment of the interview, followed by the nausea and the anosmia with a RR of 8.5. Therefore, public health strategies must be rethought, to treat or rehabilitate, avoiding chronic problems in patients recovered from COVID-19.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; persistent symptoms; post-COVID syndrome; recovered from COVID

Year:  2020        PMID: 33327641     DOI: 10.3390/ijerph17249367

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  16 in total

Review 1.  Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review.

Authors:  Eleni Korompoki; Maria Gavriatopoulou; Rachel S Hicklen; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Despina Fotiou; Kimon Stamatelopoulos; Evangelos Terpos; Anastasia Kotanidou; Carin A Hagberg; Meletios A Dimopoulos; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2021-05-14       Impact factor: 6.072

2.  Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans.

Authors:  Kanika Vanshylla; Veronica Di Cristanziano; Franziska Kleipass; Felix Dewald; Philipp Schommers; Lutz Gieselmann; Henning Gruell; Maike Schlotz; Meryem S Ercanoglu; Ricarda Stumpf; Petra Mayer; Matthias Zehner; Eva Heger; Wibke Johannis; Carola Horn; Isabelle Suárez; Norma Jung; Susanne Salomon; Kirsten Alexandra Eberhardt; Birgit Gathof; Gerd Fätkenheuer; Nico Pfeifer; Ralf Eggeling; Max Augustin; Clara Lehmann; Florian Klein
Journal:  Cell Host Microbe       Date:  2021-05-03       Impact factor: 21.023

3.  Prevalence of anosmia and ageusia symptoms among long-term effects of COVID-19.

Authors:  Vittorio Moraschini; Daiana Reis; Roberto Sacco; Monica Diuana Calasans-Maia
Journal:  Oral Dis       Date:  2021-05-18       Impact factor: 4.068

Review 4.  Post-Acute COVID-19 Syndrome for Anesthesiologists: A Narrative Review and a Pragmatic Approach to Clinical Care.

Authors:  Rafal Kopanczyk; Nicolas Kumar; Thomas Papadimos
Journal:  J Cardiothorac Vasc Anesth       Date:  2021-10-03       Impact factor: 2.894

5.  More Than 100 Persistent Symptoms of SARS-CoV-2 (Long COVID): A Scoping Review.

Authors:  Lawrence D Hayes; Joanne Ingram; Nicholas F Sculthorpe
Journal:  Front Med (Lausanne)       Date:  2021-11-01

Review 6.  Post-COVID-19 Syndrome: Involvement and Interactions between Respiratory, Cardiovascular and Nervous Systems.

Authors:  Valeria Visco; Carolina Vitale; Antonella Rispoli; Carmine Izzo; Nicola Virtuoso; Germano Junior Ferruzzi; Mario Santopietro; Americo Melfi; Maria Rosaria Rusciano; Angelantonio Maglio; Paola Di Pietro; Albino Carrizzo; Gennaro Galasso; Alessandro Vatrella; Carmine Vecchione; Michele Ciccarelli
Journal:  J Clin Med       Date:  2022-01-20       Impact factor: 4.241

7.  Prevalence of Post COVID-19 Condition in Primary Care: A Cross Sectional Study.

Authors:  Patricia Montenegro; Irene Moral; Alicia Puy; Esther Cordero; Noa Chantada; Lluis Cuixart; Carlos Brotons
Journal:  Int J Environ Res Public Health       Date:  2022-02-06       Impact factor: 3.390

8.  Improvement in Walking Distance Lags Raise in Lung Function in Post-COVID Patients.

Authors:  Wilmer Madrid-Mejía; Laura Gochicoa-Rangel; José Rogelio Pérez Padilla; Antonio Salles-Rojas; Amaury González-Molina; Isabel Salas-Escamilla; Adela Durán-Cuellar; Mónica Silva-Cerón; Carlos Guzmán-Valderrábano; Luis Lozano-Martínez
Journal:  Arch Bronconeumol       Date:  2021-05-14       Impact factor: 4.872

9.  Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis.

Authors:  César Fernández-de-Las-Peñas; Domingo Palacios-Ceña; Víctor Gómez-Mayordomo; Lidiane L Florencio; María L Cuadrado; Gustavo Plaza-Manzano; Marcos Navarro-Santana
Journal:  Eur J Intern Med       Date:  2021-06-16       Impact factor: 7.749

10.  More than 50 long-term effects of COVID-19: a systematic review and meta-analysis.

Authors:  Sandra Lopez-Leon; Talia Wegman-Ostrosky; Carol Perelman; Rosalinda Sepulveda; Paulina A Rebolledo; Angelica Cuapio; Sonia Villapol
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.